National Vaccine and Serum Institute, China clinical trials
Acquired by Sinopharm, Nov 2010 · source ↗
The registry lists 13 studies whose lead sponsor is National Vaccine and Serum Institute, China. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 23, 2026.
Before and after it joined Sinopharm
- First submitted before National Vaccine and Serum Institute, China became part of Sinopharm
- 0
- First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- 13
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- National Vaccine and Serum Institute, China13 studies
Something wrong with this grouping? Tell us on the Sinopharm page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All Sinopharm studies →
- A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsRecruitingNCT05262010Phase 3
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule BridgingActive, not recruitingNCT06632912Phase 3
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)CompletedNCT05916326Phase 3
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19CompletedNCT04869592Phase 1/2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and AboveCompletedNCT05408312Phase 1
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)Status unknownNCT05293548Phase 2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus unknownNCT05033847Phase 2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus unknownNCT05069129Phase 1/2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical TrialStatus unknownNCT05599516Phase 3
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)Status unknownNCT04941261Phase 2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)CompletedNCT04436133Phase 2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsCompletedNCT04083196Phase 1
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent VaccineCompletedNCT04188691Phase 1
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm